Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
JD HEALTH
06618
5
ALI HEALTH
00241
| (FY)Jun 30, 2025 | (Q6)Dec 31, 2024 | (FY)Jun 30, 2024 | (Q6)Dec 31, 2023 | (FY)Jun 30, 2023 | (Q6)Dec 31, 2022 | (FY)Jun 30, 2022 | (Q6)Dec 31, 2021 | (FY)Jun 30, 2021 | (Q6)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | -4,526.55%-25.67M | ---- | 100.55%580K | ---- | 43.56%-106.12M | ---- | 72.19%-188.01M | ---- | -36.99%-676.01M | ---- |
| Profit adjustment | ||||||||||
| Interest (income) - adjustment | ---- | ---- | ---- | ---- | ---- | ---- | ---744K | ---- | ---- | ---- |
| Dividend (income)- adjustment | ---- | ---- | ---- | ---- | ---- | ---- | ---807K | ---- | ---- | ---- |
| Attributable subsidiary (profit) loss | 62.03%-658K | ---- | -108.27%-1.73M | ---- | 1,189.78%20.96M | ---- | 150.47%1.63M | ---- | 70.40%-3.22M | ---- |
| Impairment and provisions: | ---- | ---- | ---- | ---- | -52.55%10.43M | ---- | -89.94%21.99M | ---- | 1,750.72%218.55M | ---- |
| -Impairment of property, plant and equipment (reversal) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --3.97M | ---- |
| -Other impairments and provisions | ---- | ---- | ---- | ---- | -52.55%10.43M | ---- | -89.75%21.99M | ---- | --214.58M | ---- |
| Revaluation surplus: | 66.01%6.9M | ---- | 1,340.90%4.16M | ---- | 18.09%-335K | ---- | -354.44%-409K | ---- | 97.77%-90K | ---- |
| -Other fair value changes | 66.01%6.9M | ---- | 1,340.90%4.16M | ---- | 18.09%-335K | ---- | -354.44%-409K | ---- | 97.77%-90K | ---- |
| Asset sale loss (gain): | 86.35%-3.74M | ---- | -1,519.15%-27.42M | ---- | 150.87%1.93M | ---- | -1,091.64%-3.8M | ---- | 294.85%383K | ---- |
| -Loss (gain) from sale of subsidiary company | 92.95%-1.98M | ---- | -1,552.69%-28.07M | ---- | 207.69%1.93M | ---- | ---1.79M | ---- | ---- | ---- |
| -Loss (gain) on sale of property, machinery and equipment | -372.22%-1.76M | ---- | --648K | ---- | ---- | ---- | ---2M | ---- | ---- | ---- |
| -Loss (gain) from selling other assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --383K | ---- |
| Depreciation and amortization: | -2.28%13.71M | ---- | -13.58%14.03M | ---- | -37.69%16.24M | ---- | -76.08%26.06M | ---- | 149.54%108.92M | ---- |
| -Amortization of intangible assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -86.90%275K | ---- |
| Financial expense | -43.68%548K | ---- | 66.32%973K | ---- | --585K | ---- | ---- | ---- | 243.68%10.62M | ---- |
| Exchange Loss (gain) | -91.15%94K | ---- | 205.99%1.06M | ---- | 36.34%-1M | ---- | -710.08%-1.57M | ---- | -78.19%258K | ---- |
| Special items | 162.06%2.54M | ---- | 31.61%-4.1M | ---- | -397.96%-5.99M | ---- | -68.17%2.01M | ---- | 407.23%6.32M | ---- |
| Operating profit before the change of operating capital | 49.55%-6.28M | ---- | 80.34%-12.45M | ---- | 55.94%-63.3M | ---- | 57.02%-143.67M | ---- | 26.98%-334.28M | ---- |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | 86.67%56.77M | ---- | 13.28%30.41M | ---- | -63.03%26.85M | ---- | 96.58%72.62M | ---- | 523.60%36.94M | ---- |
| Accounts receivable (increase)decrease | 728.30%51.8M | ---- | -137.69%-8.24M | ---- | 309.13%21.87M | ---- | -86.92%5.35M | ---- | -48.95%40.88M | ---- |
| Accounts payable increase (decrease) | -49.03%-160.91M | ---- | -1,577.56%-107.97M | ---- | -127.84%-6.44M | ---- | -83.85%23.12M | ---- | 381.83%143.14M | ---- |
| Cash from business operations | 40.33%-58.63M | ---- | -367.49%-98.25M | ---- | 50.65%-21.02M | ---- | 62.42%-42.58M | ---- | 74.08%-113.31M | ---- |
| Other taxs | -120.22%-36K | ---- | -94.39%178K | ---- | 443.66%3.18M | ---- | -91.39%584K | ---- | -78.19%6.78M | ---- |
| Interest paid - operating | 72.50%-950K | ---- | -4,834.29%-3.45M | ---- | 74.64%-70K | ---- | 74.08%-276K | ---- | 47.20%-1.07M | ---- |
| Special items of business | 17.45%-175K | 191.60%8.69M | 11.67%-212K | -169.88%-9.49M | -64.38%-240K | 171.57%13.58M | -19.67%-146K | 74.34%-18.97M | 32.60%-122K | 51.67%-73.94M |
| Net cash from operations | 41.23%-59.79M | 191.60%8.69M | -460.49%-101.74M | -169.88%-9.49M | 57.21%-18.15M | 171.57%13.58M | 60.62%-42.42M | 74.34%-18.97M | 73.62%-107.72M | 51.67%-73.94M |
| Cash flow from investment activities | ||||||||||
| Interest received - investment | -3.03%577K | ---- | -35.68%595K | ---- | -55.18%925K | ---- | 64.72%2.06M | ---- | -54.98%1.25M | ---- |
| Dividend received - investment | --3.78M | --3.78M | ---- | ---- | ---- | ---- | --807K | ---- | ---- | ---- |
| Restricted cash (increase) decrease | -185.60%-10.67M | -92.54%421K | 233.23%12.46M | 148.25%5.65M | -320.80%-9.35M | -8,459.29%-11.7M | -59.68%4.24M | 101.28%140K | 246.49%10.51M | -79.01%-10.91M |
| Sale of fixed assets | 1,037.40%5.69M | ---- | --500K | ---- | ---- | -83.90%631K | --2.24M | --3.92M | ---- | ---- |
| Purchase of fixed assets | -300.00%-68K | ---- | 72.13%-17K | 66.67%-10K | 39.60%-61K | 53.85%-30K | 94.69%-101K | 96.33%-65K | 98.01%-1.9M | 58.72%-1.77M |
| Purchase of intangible assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---21K | ---- |
| Sale of subsidiaries | 4.28%43.11M | --10M | 8,696.81%41.35M | ---- | -74.48%470K | ---- | -79.48%1.84M | ---- | --8.98M | ---- |
| Other items in the investment business | ---- | -98.04%39K | ---- | 275.31%1.99M | ---- | -160.67%-1.13M | ---- | 43.77%1.87M | -76.74%913K | -59.02%1.3M |
| Net cash from investment operations | -22.70%42.42M | 86.75%14.24M | 784.42%54.88M | 162.32%7.63M | -172.32%-8.02M | -308.70%-12.24M | -43.78%11.09M | 151.54%5.86M | 120.51%19.72M | -57.78%-11.38M |
| Net cash before financing | 62.94%-17.36M | 1,330.86%22.93M | -79.03%-46.85M | -238.93%-1.86M | 16.48%-26.17M | 110.23%1.34M | 64.39%-31.33M | 84.64%-13.11M | 82.56%-87.99M | 46.74%-85.31M |
| Cash flow from financing activities | ||||||||||
| New borrowing | -18.30%25M | ---- | --30.6M | ---- | ---- | -95.86%1.66M | --40M | --40M | ---- | ---- |
| Refund | ---30.6M | ---8.6M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Issuing shares | ---- | ---- | -15.20%9.81M | ---- | -41.83%11.57M | ---- | --19.89M | --8.4M | ---- | ---- |
| Interest paid - financing | ---- | ---- | ---- | ---- | ---- | ---8K | ---- | ---- | ---- | ---- |
| Net cash from financing operations | -113.92%-5.6M | -5,595.36%-8.6M | 256.99%40.23M | -110.14%-151K | -79.86%11.27M | -96.92%1.49M | 648.07%55.96M | 69,118.57%48.31M | -244.14%-10.21M | -100.41%-70K |
| Effect of rate | 121.43%3K | 142.86%12K | -114.00%-14K | -163.64%-28K | 33.33%100K | 540.00%44K | 440.91%75K | 94.38%-10K | -112.64%-22K | -187.25%-178K |
| Net Cash | -246.98%-22.96M | 811.57%14.33M | 55.58%-6.62M | -171.17%-2.01M | -160.50%-14.9M | -91.96%2.83M | 125.08%24.63M | 141.23%35.21M | 80.26%-98.2M | 40.31%-85.38M |
| Begining period cash | -15.43%36.36M | -15.43%36.36M | -25.61%43M | -25.61%43M | 74.65%57.8M | 74.65%57.8M | -74.80%33.09M | -74.80%33.09M | -79.11%131.32M | -79.11%131.32M |
| Cash at the end | -63.14%13.4M | 23.82%50.71M | -15.43%36.36M | -32.50%40.95M | -25.61%43M | -11.15%60.67M | 74.65%57.8M | 49.23%68.29M | -74.80%33.09M | -90.58%45.76M |
| Cash balance analysis | ||||||||||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
| Auditor | Furimazer Certified Public Accountants Limited | -- | Furimazer Certified Public Accountants Limited | -- | CCA Zhonghuan (Hong Kong) Certified Public Accountants Limited | -- | CCA Zhonghuan (Hong Kong) Certified Public Accountants Limited | -- | CCA Zhonghuan (Hong Kong) Certified Public Accountants Limited | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.